MA42301A - Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone - Google Patents

Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone

Info

Publication number
MA42301A
MA42301A MA042301A MA42301A MA42301A MA 42301 A MA42301 A MA 42301A MA 042301 A MA042301 A MA 042301A MA 42301 A MA42301 A MA 42301A MA 42301 A MA42301 A MA 42301A
Authority
MA
Morocco
Prior art keywords
iodophenylamino
azetidin
methanone
piperidin
difluoro
Prior art date
Application number
MA042301A
Other languages
English (en)
Inventor
Adrian St Clair Brown
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56411938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42301(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA42301A publication Critical patent/MA42301A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
MA042301A 2015-06-30 2016-06-30 Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone MA42301A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562187009P 2015-06-30 2015-06-30

Publications (1)

Publication Number Publication Date
MA42301A true MA42301A (fr) 2018-05-09

Family

ID=56411938

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042301A MA42301A (fr) 2015-06-30 2016-06-30 Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone

Country Status (24)

Country Link
US (3) US10590102B2 (fr)
EP (1) EP3317264A1 (fr)
JP (3) JP7338950B2 (fr)
KR (1) KR20180021775A (fr)
CN (1) CN107810183A (fr)
AR (1) AR105483A1 (fr)
AU (2) AU2016288209B2 (fr)
CA (1) CA2990222C (fr)
CL (1) CL2017003475A1 (fr)
CO (1) CO2018000086A2 (fr)
CR (1) CR20180056A (fr)
HK (1) HK1252433A1 (fr)
IL (2) IL295052A (fr)
MA (1) MA42301A (fr)
MX (1) MX2017017037A (fr)
MY (1) MY192545A (fr)
PE (1) PE20180692A1 (fr)
PH (1) PH12017502414A1 (fr)
RU (2) RU2021132394A (fr)
SG (1) SG10202105196YA (fr)
TW (2) TWI710556B (fr)
UA (1) UA124728C2 (fr)
WO (1) WO2017004393A1 (fr)
ZA (1) ZA201708760B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
HRP20240045T1 (hr) * 2015-06-30 2024-03-29 Genentech, Inc. Tablete s trenutnim oslobađanjem koje sadrže lijek i postupci za proizvodnju tableta
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
NZ755835A (en) 2017-01-17 2023-12-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
GB201717809D0 (en) * 2017-10-30 2017-12-13 Azad Pharmaceutical Ingredients Ag Process for the production of cobimetinib
WO2020187674A1 (fr) 2019-03-15 2020-09-24 Sandoz Ag Hémisuccinate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl) azétidin-1-yl]méthanone cristallin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101318012B1 (ko) 2004-10-20 2013-10-14 메르크 세로노 에스.에이. 3-아릴아미노 피리딘 유도체
KR101368519B1 (ko) 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염
EA019983B1 (ru) 2005-10-07 2014-07-30 Экселиксис, Инк. Ингибиторы mek и способы их применения
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
WO2008076415A1 (fr) 2006-12-14 2008-06-26 Exelixis, Inc. Procédés d'utilisation d'inhibiteurs de mek
WO2008124085A2 (fr) 2007-04-03 2008-10-16 Exelixis, Inc. Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
JP6835472B2 (ja) 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
SG11201507477XA (en) 2013-03-14 2015-10-29 Genentech Inc Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
JP2018519318A (ja) 2018-07-19
TWI710556B (zh) 2020-11-21
CA2990222C (fr) 2023-09-26
KR20180021775A (ko) 2018-03-05
AU2021200202B2 (en) 2022-09-08
IL295052A (en) 2022-09-01
IL256423B (en) 2022-09-01
PE20180692A1 (es) 2018-04-23
US10590102B2 (en) 2020-03-17
EP3317264A1 (fr) 2018-05-09
CA2990222A1 (fr) 2017-01-05
AU2016288209A1 (en) 2018-02-08
AU2021200202A1 (en) 2021-03-18
CL2017003475A1 (es) 2018-07-13
RU2018103172A (ru) 2019-07-31
HK1252433A1 (zh) 2019-05-24
JP7338950B2 (ja) 2023-09-05
TWI775187B (zh) 2022-08-21
US20220056010A1 (en) 2022-02-24
TW202108568A (zh) 2021-03-01
WO2017004393A1 (fr) 2017-01-05
RU2021132394A (ru) 2021-11-18
US20200255398A1 (en) 2020-08-13
JP2021035967A (ja) 2021-03-04
CR20180056A (es) 2018-05-25
PH12017502414A1 (en) 2018-06-25
AR105483A1 (es) 2017-10-11
UA124728C2 (uk) 2021-11-10
US20180346442A1 (en) 2018-12-06
AU2016288209B2 (en) 2020-10-22
IL256423A (en) 2018-02-28
JP2023025000A (ja) 2023-02-21
SG10202105196YA (en) 2021-06-29
RU2762181C2 (ru) 2021-12-16
MY192545A (en) 2022-08-26
BR112017028516A2 (pt) 2018-08-28
CO2018000086A2 (es) 2018-04-10
TW201718535A (zh) 2017-06-01
US11254649B2 (en) 2022-02-22
RU2018103172A3 (fr) 2019-10-31
CN107810183A (zh) 2018-03-16
ZA201708760B (en) 2022-06-29
MX2017017037A (es) 2018-04-30

Similar Documents

Publication Publication Date Title
IL283979B (en) 3,1-thiazol-2-yl converted benzamides
MA42301A (fr) Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone
HK1253048A1 (zh) 1，4-取代的哌啶衍生物
DK3355884T3 (da) Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
ZA201605622B (en) 1,3-benzodioxole derivative
ZA201700019B (en) Substituted [1,2,4]triazole compounds
FR3021455B1 (fr) Procede d'aplanissement d'evidements remplis de cuivre
IL247728B (en) Piperdines -(3,5 di-converted-pyridine-4-yl)-1
HK1258964A1 (zh) 用於製備1，3-苯並間二氧雜環戊烯雜環化合物的方法
ZA201608442B (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
PL3245198T3 (pl) Pochodne pirolidyny jako antagonisty angiotensyny ii typu 2
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
FR3017730B1 (fr) Procede d'ouverture de session securise
FR3021317B1 (fr) Procede d'obtention du borazane
FR3021316B1 (fr) Procede d'obtention du borazane
IT201700060516A1 (it) Utensile per decespugliatore
GB201508211D0 (en) 33 1/3 / 45 / E.P. / 78 R.P.M vinyl records
ITBA20140023U1 (it) "cassetta per alimenti"
AU4985P (en) PP.1026 Cucurbita moschata
UA31973S (uk) Кондитерський виріб «зайченя»
ITPI20150009U1 (it) Involucro per insaccati cotti
GB201505372D0 (en) RPMS 8 Way
UA28524S (uk) Упаковка для морозива «столичне»